Search research articles
Contact Us
Filters
Showing results (331-340 of 386) with videos related to
Page
of 39
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
Nobuaki Matsubara, Johann de Bono, David Olmos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Vishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Heliyon
|
February 2, 2019
Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest, and decreasing migration through heat shock protein 40
Diane N Ignacio, Kimberly D Mason, Ezra C Hackett-Morton, et al.
Kidney Cancer (Clifton, Va.)
|
October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward
L C Harshman, C G Drake, N B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
The Lancet. Oncology
|
December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
Benjamin A Teply, Hao Wang, Brandon Luber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer
Dana Rathkopf, Glenn Liu, Michael A Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer
Andrew J Armstrong, George J Netto, Michelle A Rudek, et al.
Page
of 39
Search research articles
Search
Showing results (331-340 of 386) with videos related to
Sort By:
Page
of 39
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
Nobuaki Matsubara, Johann de Bono, David Olmos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Vishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Heliyon
|
February 2, 2019
Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest, and decreasing migration through heat shock protein 40
Diane N Ignacio, Kimberly D Mason, Ezra C Hackett-Morton, et al.
Kidney Cancer (Clifton, Va.)
|
October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward
L C Harshman, C G Drake, N B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
The Lancet. Oncology
|
December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
Benjamin A Teply, Hao Wang, Brandon Luber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer
Dana Rathkopf, Glenn Liu, Michael A Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer
Andrew J Armstrong, George J Netto, Michelle A Rudek, et al.
Page
of 39